Published online Mar 26, 2024. doi: 10.12998/wjcc.v12.i9.1597
Peer-review started: November 18, 2023
First decision: January 5, 2024
Revised: January 17, 2024
Accepted: February 28, 2024
Article in press: February 28, 2024
Published online: March 26, 2024
Processing time: 128 Days and 7.1 Hours
Acute non-variceal upper gastrointestinal bleeding (ANVUGIB) constitutes a prevalent emergency within Gastroenterology, encompassing 80%-90% of all gastrointestinal hemorrhage incidents. This condition is distinguished by its abrupt onset, swift progression, and notably elevated mortality rate.
To gather clinical data from patients with ANVUGIB at our hospital in order to elucidate the clinical characteristics specific to our institution and analyze the therapeutic effectiveness of endoscopic hemostasis.
We retrospectively retrieved the records of 532 patients diagnosed with ANVU
Among the 532 patients diagnosed with ANVUGIB, the male-to-female ratio was 2.91:1, with a higher prevalence among males. Notably, 43.6% of patients presen
ANVUGIB patients exhibit diverse characteristics across different age groups, and endoscopic hemostatic treatments have demonstrated remarkable efficacy.
Core Tip: This retrospective study analyzed the data of patients diagnosed with acute non-varicose upper gastrointestinal bleeding (ANVUGIB) through endoscopic examinations at our hospital. The results revealed distinct characteristics among patients of different age groups with ANVUGIB. Although this study was conducted at a single center, the age and gender distribution of the patients in this study were similar to those reported in previous multicenter studies in China. The study also assessed the therapeutic effectiveness of endoscopic hemostatic treatment, and indicated that it is an effective approach for treating ANVUGIB, improving efficacy, and deserves wider application.